Figure 5 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations

AZD2811 plus venetoclax combination in DLBCL. A, Combo Emax versus HSA in 25 B-cell NHL cell lines including 11 DLBCL cell lines. Cell lines with high combination activity (combo Emax > 0.5 and HSA > 0.1) are in red. B, Growth inhibition and HSA excess matrices in DLBCL cell line WSUDLCL2. C, Western blot analysis for cleaved PARP in WSUDLCL2 cells treated with AZD2811 or venetoclax alone or in combination. D, Matrix plots indicating combination activity (measured by growth inhibition) in WSUDLCL2 cells pretreated with pan caspase inhibitor Q-VD-OPH and exposed to AZD2811 combined with venetoclax for 72 hours. Matrix values represent cell viability normalized to day 0 on the scale of 0 to 200 (value < 100 = percentage of growth inhibition, value > 100 = cell death). E, Tumor growth in WSUDLCL2 xenografts treated with AZD2811 or venetoclax alone or in combination for 46 days (n = 6 per group, * 0.05 < P < 0.01, ** 0.01 < P < 0.001). Data are plotted as mean tumor volume ± SEM. PO, orally; QD, every day; QW, every week.